Apyx Medical Corporation APYX 深 沪
已收盘 02-06 16:00:00 美东时间
3.88
-0.060
-1.52%
华盛通- 最 高4.14
- 今 开4.00
- 成交量 10.76万股
- 最 低 3.8601
- 昨 收 3.94
- 总市值 1.59亿
- 52周最高 4.50
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 0.7554
- 委 比 93.30%
- 总股本 4102.96万
- 历史最高 17.50
- 量 比 0.47
- 振 幅 7.10%
- 历史最低 0.7554
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Apyx Medical Corporation, a leader in surgical aesthetics with products like Renuvion® and AYON Body Contouring System, announced its participation in the BTIG 13th Annual MedTech Conference on February 10, 2026, in Snowbird, Utah. Investors can request meetings via their BTIG representatives. The company specializes in innovative medical technologies, including FDA-cleared devices for cosmetic and hospital surgical markets, supported by over 90 ...
01-29 13:00
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
<p>Apyx Medical Corporation reported strong fourth-quarter and full-year 2025 revenue growth. Surgical Aesthetics revenue increased 38% year-over-year in Q4, driven by a 51% jump in the U.S. following the launch of AYON. Total Q4 revenue was $19.0-$19.2 million, up 34% from the prior year. Full-year revenue reached $52.7-$52.9 million, an 10% increase, with Surgical Aesthetics up 17%. The company attributes its success to the adoption of AYON and...
01-12 13:00
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Roth Capital Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $6
Roth Capital analyst Kyle Bauser initiates coverage on Apyx Medical (NASDAQ:APYX) with a Buy rating and announces Price Target of $6.
2025-12-16 23:19
AI adopters trade gaining steam; top stocks in AI adoption sectors
Wall Street research looks to be shifting from endorsing the classic AI trade to AI adopters. Instead of the chipmakers and hyperscalers in the megacap sectors (XLK) (XLC) (XLY) that are making AI pos...
2025-12-09 17:28
Apyx Medical Announces Approval, Commercial Roll Out Of Apyx One Console, Single-Use Handpieces In South Korea
Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the
2025-12-03 21:05
Apyx Medical Raises $9.4M Through Stock Offering
An announcement from Apyx Medical ( ($APYX) ) is now available. On November 18,...
2025-11-20 06:08
Apyx Medical Reveals Proposed Public Offering of Common Stock; No Size Disclosed
Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it
2025-11-18 05:07
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
Apyx Medical outlines $50.5M–$52.5M 2025 revenue target, signals AYON launch momentum
Earnings Call Insights: Apyx Medical Corporation (APYX) Q3 2025 Management View Charles Goodwin, President and CEO, announced the official rebranding of the Advanced Energy segment to Surgical Aesthet...
2025-11-07 03:36
